Last reviewed · How we verify

Hyperbaric bupivacaine+Sufentanil

Fundación Pública Andaluza Progreso y Salud · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation; the hyperbaric formulation increases density for spinal distribution.

Bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation; the hyperbaric formulation increases density for spinal distribution. Used for Spinal anesthesia for surgical procedures, Postoperative pain management.

At a glance

Generic nameHyperbaric bupivacaine+Sufentanil
Also known asSufentanil
SponsorFundación Pública Andaluza Progreso y Salud
Drug classLocal anesthetic + opioid combination
TargetVoltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that reversibly inhibits sodium influx in nerve membranes, preventing action potential propagation and sensory/motor blockade. Sufentanil is a potent synthetic opioid that binds mu-opioid receptors in the spinal cord and central nervous system to provide analgesia. The hyperbaric (dextrose-containing) formulation increases specific gravity, allowing controlled spread within cerebrospinal fluid for targeted spinal anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: